Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 3/20 | 0.42 |
| ▸ | CCR5 | P51681 | 3/20 | 0.42 |
| ▸ | CCR8 | P51685 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | UNG | P13051 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
| ▸ | KDM6B | O15054 | 1/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | KDM5C | P41229 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29387096 | 1.00 | CCR1 (0.42) | CCR1CCR5CCR8ALDH1A1KDM4E | |
| SCHEMBL30259554 | 0.98 | CCR1 (0.41) | CCR1CCR5CCR8ALDH1A1KDM4E | |
| SCHEMBL30259309 | 0.98 | CCR1 (0.41) | CCR1CCR5CCR8ALDH1A1KDM4E | |
| SCHEMBL17057411 | 0.91 | CYP2A6 (0.37) | CCR1CCR5CCR8ALDH1A1KDM4E | |
| SCHEMBL23787847 | 0.89 | KDM4E (0.42) | CCR1CCR5CCR8ALDH1A1KDM4E | |
| SCHEMBL1508069 | 0.88 | CCR1 (0.65) | CCR1CCR5CCR8ALDH1A1KDM4E | |
| SCHEMBL29943121 | 0.88 | CCR1 (0.65) | CCR1CCR5CCR8ALDH1A1KDM4E | |
| SCHEMBL30472762 | 0.88 | KDM4E (0.54) | CCR1CCR5CCR8ALDH1A1KDM4E | |
| SCHEMBL4541928 | 0.88 | KDM4E (0.54) | CCR1CCR5CCR8ALDH1A1KDM4E | |
| SCHEMBL3721732 | 0.86 | KDM4E (0.44) | CCR1CCR5CCR8ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12161637-B2 | Anti-cancer gold complex, process of synthesis and method of treatment thereof | KING SAUD UNIVERSITY (SA) | 2024-12-10 | — | — | US | claimed |
| US-20230087073-A1 | ANTI-CANCER GOLD COMPLEX, PROCESS OF SYNTHESIS AND METHOD OF TREATMENT THEREOF | KING SAUD UNIVERSITY (SA) | 2023-03-23 | — | — | US | claimed |
| CN-106000386-B | A kind of catalyst and the method using catalyst preparation 2,2 '-bipyridyl-the 4,4 '-diacrylate | 河南省商业科学研究所有限责任公司 | 2018-08-14 | — | — | CN | claimed |
| CN-106000386-A | Catalyst, and method for preparing 2,2'-dipyridyl-4,4'-diacrylic acid by using catalyst | 河南省商业科学研究所有限责任公司 | 2016-10-12 | — | — | CN | claimed |
| US-20110006295-A1 | COMPOUNDS HAVING ELECTROLUMINESCENT OR ELECTRON TRANSPORT PROPERTIES | MERCK PATENT GMBH | 2011-01-13 | — | — | US | claimed |
| EP-2250151-A1 | COMPOUNDS HAVING ELECTROLUMINESCENT OR ELECTRON TRANSPORT PROPERTIES | Merck Patent GmbH (DE) | 2010-11-17 | — | — | EP | claimed |
| WO-2009112854-A1 | COMPOUNDS HAVING ELECTROLUMINESCENT OR ELECTRON TRANSPORT PROPERTIES | MERCK PATENT GMBH (DE) | 2009-09-17 | — | — | WO | claimed |
| US-12636366-B2 | Ruthenium (II) complexes and conjugates thereof for use as photosensitizer agent in photodynamic therapy | ECOLE NATIONALE SUPERIEURE DE CHIMIE DE PARIS (FR) | 2026-05-26 | — | — | US | disclosed |
| US-12161637-B2 | Anti-cancer gold complex, process of synthesis and method of treatment thereof | KING SAUD UNIVERSITY (SA) | 2024-12-10 | — | — | US | disclosed |
| US-20230087073-A1 | ANTI-CANCER GOLD COMPLEX, PROCESS OF SYNTHESIS AND METHOD OF TREATMENT THEREOF | KING SAUD UNIVERSITY (SA) | 2023-03-23 | — | — | US | disclosed |
| US-20220296711-A1 | Ruthenium (II) Complexes and Conjugates Thereof for Use as Photosensitizer Agent in Photodynamic Therapy | UNIVERSITY OF ZÜRICH (CH) | 2022-09-22 | — | — | US | disclosed |
| EP-3986904-A1 | RUTHENIUM (II) COMPLEXES AND CONJUGATES THEREOF FOR USE AS PHOTOSENSITIZER AGENT IN PHOTODYNAMIC THERAPY | Paris Sciences et Lettres (FR) | 2022-04-27 | — | — | EP | disclosed |
| EP-3757111-A1 | RUTHENIUM (II) COMPLEXES AND CONJUGATES THEREOF FOR USE AS PHOTOSENSITIZER AGENT IN PHOTODYNAMIC THERAPY | Paris Sciences et Lettres - Quartier Latin (FR) | 2020-12-30 | — | — | EP | disclosed |
| WO-2008137740-A1 | FULVENE AND FULVALENE ANALOGS AND THEIR USE IN TREATING CANCERS | EMORY UNIVERSITY (US) | 2008-11-13 | — | — | WO | disclosed |
| US-20080275016-A1 | For drug resistant cancers; antiinflammatory agents;degenerative or vascular diseases; blocking nitrogen oxide so growth of tumors is suppressed | U.S. GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS, THE | 2008-11-06 | — | — | US | disclosed |
| US-20080275016-A1 | For drug resistant cancers; antiinflammatory agents;degenerative or vascular diseases; blocking nitrogen oxide so growth of tumors is suppressed | U.S. GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS, THE | 2008-11-06 | — | — | US | disclosed |
| WO-2008102962-A1 | NOBLE RUTHENIUM-TYPE SENSITIZER AND METHOD OF PREPARING THE SAME | DONGJIN SEMICHEM CO., LTD. (KR) | 2008-08-28 | — | — | WO | disclosed |
| US-20070209695-A1 | Dye and Dye-Sensitized Solar Cell | JSR CORPORATION (JP) | 2007-09-13 | — | — | US | disclosed |
| EP-1767588-A1 | DYE AND DYE-SENSITIZED SOLAR CELL | JSR Corporation (JP) | 2007-03-28 | — | — | EP | disclosed |
| EP-0360820-B1 | OLIGOBIPYRIDINE LIGANDS, PROCESS FOR OBTAINING THEM AND APPLICATION AS COMPLEXING AGENTS | CIS BIO INTERNATIONAL (FR) | 1992-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296711-A1 | Ruthenium (II) Complexes and Conjugates Thereof for Use as Photosensitizer Agent in Photodynamic Therapy | ANXA5, CD47, SPR | CCR1 3484/4885CCR5 1969/4885CCR8 4073/4885 |
| US-12636366-B2 | Ruthenium (II) complexes and conjugates thereof for use as photosensitizer agent in photodynamic therapy | FABP2, APC, TP53 | CCR1 1967/4885CCR5 1492/4885CCR8 1892/4885 |
| US-20230087073-A1 | ANTI-CANCER GOLD COMPLEX, PROCESS OF SYNTHESIS AND METHOD OF TREATMENT THEREOF | NDUFAB1, AIFM1, NDUFV2 | CCR1 4860/4885CCR5 4705/4885CCR8 4717/4885 |
| US-20070209695-A1 | Dye and Dye-Sensitized Solar Cell | MLX, CRY2, MSL1 | CCR1 2375/4885CCR5 2949/4885CCR8 4628/4885 |
| US-20110006295-A1 | COMPOUNDS HAVING ELECTROLUMINESCENT OR ELECTRON TRANSPORT PROPERTIES | NR2E3, NR4A2, NR4A3 | CCR1 1330/4885CCR5 2102/4885CCR8 1334/4885 |
| US-12161637-B2 | Anti-cancer gold complex, process of synthesis and method of treatment thereof | NDUFAB1, AIFM1, NDUFV2 | CCR1 4860/4885CCR5 4705/4885CCR8 4717/4885 |
| US-20080275016-A1 | For drug resistant cancers; antiinflammatory agents;degenerative or vascular diseases; blocking nitrogen oxide so growth of tumors is suppressed | NOX1, NOX3, ROS1 | CCR1 1150/4885CCR5 1987/4885CCR8 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.